On November 21, 2025, $Eli Lilly and Co (LLY.US)$ 's stock price rose 1.6%, pushing its market capitalization past $1 trillion for the first time. This makes Lilly the first pharmaceutical company to join the "Trillion-Dollar Market Cap Club" and the 10th company overall to achieve this milestone.
For a long time, tech giants almost exclusively held the tickets to the trillion-dollar market cap cl...

$Omeros (OMER.US)$
Narsoplimab was approved by the FDA for the treatment of HSCT-TMA (Hematopoietic stem cell transplant–associated thrombotic microangiopathy) on December 24, 2025.
As discussed on our website, Narsoplimab’s clinical data met the prespecified primary endpoint, supporting evidence of efficacy alongside a tolerable safety profile. Despite these encouraging clinical results, the study was single-arm and lacked a control group, meaning that all patients received Narsoplimab and none ...

A strong rejection from the strong support level, stock price has formed a bullish pinbar in monthly timeframe, and RSI is heavily oversold. Most importantly, price is dirt cheap right now and fundamental still looking solid. At such valuation, $Novo-Nordisk A/S (NVO.US)$ is looking absolutely tempting.

The healthcare sector just got a major adrenaline shot! 💪 While tech titans and AI darlings dominated headlines, medical stocks quietly staged a comeback with rock-solid earnings and defensive appeal. Let's dissect why investors are rewriting their prescriptions for portfolio growth!
🔥 Earnings Fireworks & Sector Stars Shining Bright:
$Medtronic (MDT.US)$ Spiked after crushing Q4 numbers, boosting FY outlook on surging demand for medical dev...

On November 18, before market open, $Medtronic (MDT.US)$ released its Q2 fiscal 2026 earnings, once again surpassing market expectations. The stock rose over 4% in pre-market trading.
Key Figures:
Q2 revenue: $8.961 billion, up 6.6% YoY (5.5% organic growth), exceeding the expected $8.865 billion
Non-GAAP diluted EPS: $1.36, up 8% YoY, surpassing the expected $1.31
Profit margins returned to l...

$Medtronic (MDT.US)$ is scheduled to report its fiscal Q2 2026 earnings before the market opens on Tuesday, November 18, 2025.
Medtronic (MDT) Fiscal Q2 2026 Earnings Analysis
The general consensus from analysts points to continued growth, supported by momentum in key product lines.
Based on 8 analyst from Moomoo app, the consensus estimate for earnings per share (EPS) is expectd to come in at $0.948 per share.
Based on 15 analysts from Mo...

$Medtronic (MDT.US)$
Medtronic Q2 FY2026 earnings conference call is scheduled for November 18 at 7:30 AM ET /November 18 at 8:30 PM SGT /November 18 at 11:30 PM AEDT. Subscribe to join the live earnings conference with management NOW!
Beat or Miss?
What do you expect from Medtronic's Q2 earnings? Will the company beat or miss the estimates? Make sure to click the "Book" button to get what management has to say!
Disclaimer:
This presentation is for informat...